About The Louisiana Research Center, LLC

The Louisiana Research Center, LLC is a clinical research center owned and operated by gastroenterologists who are also partners in the group practice of GastroIntestinal Specialists, A.M.C. The Center is able to serve you with two locations. The practice has participated in investigational studies since 1992, and the successful completion of these studies led to the formation of Louisiana Research Center. There are three full-time research coordinators on staff.

The consistent ability to recruit and enroll patients and complete studies in a timely and professional manner has resulted in a high level of satisfaction for both clinical research organizations and sponsoring pharmaceutical companies.

Since 1992 we have participated in and completed studies involving peptic ulcer disease (with Helicobacter pylori), erosive esophagitis, gastroesophageal reflux disease, non-erosive esophagitis, anal-rectal disease, chronic constipation, diarrhea, irritable bowel syndrome, inflammatory bowel disease, and hepatitis C.

We have also performed studies in healthy volunteers to study the possible effects of medications on the gastrointestinal tract. Louisiana Research Center is actively pursuing participation in additional gastrointestinal studies.

Fast Facts

  • Associated with the largest group of board certified gastroenterologists in the Ark-La-Tex.
  • Utilizes a centralized institutional review board (IRB).
  • Adheres to Good Clinical Practice Guidelines.
  • Has access to a large population base with a diverse array of pathology.
  • Utilizes the Shreveport Endoscopy Center for studies requiring endoscopic procedures.
  • Has been highly successful in patient recruitment.
  • Has an excellent record of timely completion of studies with accurate and complete source documents.

Current Studies


Initiation of induction of infliximab or adalimumab within the last 24 weeks

Active endoscopic disease

Pharmacosmos IDA

Must have IDA caused by different aetiologies* such as abnormal uterine bleed-ing, gastrointestinal diseases, cancer, bariatric procedures (gastric bypass operations), and other conditions leading to significant blood loss.

A documented history of intolerance to oral iron therapy for at least one month within 9 months prior to trial enrollment

Hb ≤ 11 g/d

5. TSAT < 20

6. S-ferritin < 100 ng/mL

GenFit, Intercept, Shire, Aurora, and Gilead NASH

Fibrosis stage 1-3

Shire allows F0.

Gilead & Intercept study enrolling compensated cirrhosis patients

Uncontrolled diabetes, history of cancer other Chronic Liver Diseases excluded

Pt must be willing to have 2 liver Biopsies

Takeda Observational Study A For Crohn`s and UC

Initiated a biologic within 2 weeks of enrollment

Shire Eosinophilic Esophagitis

Histologic evidence of EOE

Currently on and Non responsive to high dose PPI`s

Celgene, Janssen, Takeda, Gilead, Abbvie, Eli Lily and Genentech Crohn’s

18 years or older

Moderate to severely active Crohn’s disease

Abbvie, Genetech, Gilead, Takeda, and Protagonist- Moderate to Severe Ulcerative Colitis

18-80 years of age

Diagnosis of UC established at least 3-6 months prior to Day 1

Evidence of UC extending a minimum of 20 cm from the anal verge determine by baseline Endoscopy

Corrona IBD

18 years of age

Diagnosis of Crohn’s Disease, UC, or Indeterminate colitis

Target IBD

18 years of age

Diagnosis of Crohn’s Disease, UC, or Indeterminate colitis

Target Nash

Managed or Treated for NAFL OR NASH

H pylori

Symptoms consistent with dyspepsia of at least two week duration

Females cannot be on hormonal contraceptives

Cannot have received prior H pylori eradication

Please call (318) 525-3233 for more information.